Incretin-Related Drug Therapy in Heart Failure

被引：7
作者：
Vest A.R. [1 ]
机构：
[1] Division of Cardiology, Tufts Medical Center, 800 Washington Street, South 6138, Boston, 02111, MA
来源：
Current Heart Failure Reports | 2015年 / 12卷 / 1期
关键词：
Diabetes; DPP-4; GLP-1; Heart failure; Incretins; Left ventricular dysfunction; Myocardial metabolism; Obesity; Reperfusion injury;
D O I：
10.1007/s11897-014-0232-6
中图分类号：
学科分类号：
摘要：
The new pharmacological classes of GLP-1 agonists and DPP-4 inhibitors are now widely used in diabetes and have been postulated as beneficial in heart failure. These proposed benefits arise from the inter-related pathophysiologies of diabetes and heart failure (diabetes increases the risk of heart failure, and heart failure can induce insulin resistance) and also in light of the dysfunctional myocardial energetics seen in heart failure. The normal heart utilizes predominantly fatty acids for energy production, but there is some evidence to suggest that increased myocardial glucose uptake may be beneficial for the failing heart. Thus, GLP-1 agonists, which stimulate glucose-dependent insulin release and enhance myocardial glucose uptake, have become a focus of investigation in both animal models and humans with heart failure. Limited pilot data for GLP-1 agonists shows potential improvements in systolic function, hemodynamics, and quality of life, forming the basis for current phase II trials. © 2014, Springer Science+Business Media New York.
引用
收藏
页码：24 / 32
页数：8
相关论文
共 59 条
  • [1] Go A.S., Mozaffarian D., Roger V.L., Benjamin E.J., Berry J.D., Borden W.B., Et al., Heart disease and stroke statistics - 2013 update: a report from the American Heart Association, Circulation, 127, 1, (2013)
  • [2] Ashrafian H., Frenneaux M.P., Opie L.H., Metabolic mechanisms in heart failure, Circulation, 116, 4, pp. 434-448, (2007)
  • [3] Bing R.J., The metabolism of the human heart in vivo, J Mt Sinai Hosp N Y, 20, 2, pp. 100-117, (1953)
  • [4] Ferrari R., Prognostic benefits of heart rate reduction in cardiovascular disease, Eur Heart J Suppl, 5, pp. G10-G14, (2003)
  • [5] Ingwall J.S., Weiss R.G., Is the failing heart energy starved? on using chemical energy to support cardiac function, Circ Res, 95, 2, pp. 135-145, (2004)
  • [6] Neubauer S., The failing heart—an engine out of fuel, N Engl J Med, 356, 11, pp. 1140-1151, (2007)
  • [7] Stanley W.C., Recchia F.A., Lopaschuk G.D., Myocardial substrate metabolism in the normal and failing heart, Physiol Rev, 85, 3, pp. 1093-1129, (2005)
  • [8] Stanley W.C., Chandler M.P., Energy metabolism in the normal and failing heart: potential for therapeutic interventions, Heart Fail Rev, 7, 2, pp. 115-130, (2002)
  • [9] Taylor M., Wallhaus T.R., Degrado T.R., Russell D.C., Stanko P., Nickles R.J., Et al., An evaluation of myocardial fatty acid and glucose uptake using PET with [18 F]fluoro-6-thia-heptadecanoic acid and [18 F]FDG in patients with congestive heart failure, J Nucl Med, 42, 1, pp. 55-62, (2001)
  • [10] Paolisso G., Gambardella A., Galzerano D., D'Amore A., Rubino P., Verza M., Et al., Total-body and myocardial substrate oxidation in congestive heart failure, Metab Clin Exp, 43, 2, pp. 174-179, (1994)
123456